Elafin to prevent acute rejection following lung transplantation

$358,860P01FY2011HLNIH

Stanford University, Stanford CA

Investigators

Linked publications & trials

Paper 39209474 Paper 39209468 Paper 38471030 Paper 38085642 Paper 37989727 Paper 37934691 Paper 36744494 Paper 35696338 Paper 34872889 Paper 34215862 Paper 34181952 Paper 33952674 Paper 33839076 Paper 33651671 Paper 33548142 Paper 33334941 Paper 33294774 Paper 33044226 Paper 32763154 Paper 32602650 Paper 32382044 Paper 31988495 Paper 31980301 Paper 31917512 Paper 31798835 Paper 31513751 Paper 31094755 Paper 30806154 Paper 30661465 Paper 30635853 Paper 30586708 Paper 30582451 Paper 30545975 Paper 30545970 Paper 30131961 Paper 29894205 Paper 29877097 Paper 29767574 Paper 29545367 Paper 29467298 Paper 29369345 Paper 28935667 Paper 28934596 Paper 28469087 Paper 27804215 Paper 26967995 Paper 26873944 Paper 26177174 Paper 25981508 Paper 25888148 Paper 25853696 Paper 25727073 Paper 25539853 Paper 24951765 Paper 24880953 Paper 24684441 Paper 24612731 Paper 24570092 Paper 24569371 Paper 24468195 Paper 24446489 Paper 24355640 Paper 24267896 Paper 24161166 Paper 24158514 Paper 24155924 Paper 24051955 Paper 23986401 Paper 23867624 Paper 23797537 Paper 23769046 Paper 23530212 Paper 23402031 Paper 23400799 Paper 23372927 Paper 23202738 Paper 23102413 Paper 23002078 Paper 22990707 Paper 22842496 Paper 22743666 Paper 22683569 Paper 22307907 Paper 22185646 Paper 21998328 Paper 21868697 Paper 21821917 Paper 21763677 Paper 21606594 Paper 21562133

Abstract

Lung transplantation currently represents the only cure for a number of advanced lung diseases. Unfortunately, it is also the least successful solid organ transplant because of the very high incidence of BOS which affects >50% of lung transplant recipients in 5 years (18). Poor outcomes in lung transplantafion may be intimately related to the tenuous circulation supplying the airways (4, 5, 19). Given the link between loss of microvascular integrity and chronic rejection, the development of adjunctive vasculoprotective therapies, such as those described in this proposal, hold promise for significantly improving outcomes in lung transplantation.

View original record on NIH RePORTER →